RESULTS: Reproducibility of both classifications was poor. The WHO2004 showed better reproducibility (k¼0.35, 95% confidence interval (CI) 0.29-0.42) compared to the WHO1973 as a threetiered (k¼0.24, 95% CI 0.19-0.28), but not as a two-tiered (G1þG2 vs G3) classification (k¼0.36, 95% CI 0.29-0.42). Reproducibility of individual criteria was poor (k, range: -0.05-0.25). All individual criteria were associated with grade (p<0.05). After a median followup of 60 months, 33/232 and 112/232 patients developed progression and recurrence, respectively. In 3/3 pathologists progression was predicted by the WHO1973-grade in univariable and 1/3 in multivariable analysis. The WHO2004-grade predicted progression in 2/3 and 1/3 pathologists in uni-and multivariable analysis, respectively. Recurrence was not predicted by grade, except for one pathologist (univariable).
INTRODUCTION AND OBJECTIVES: Neuroendocrine (NE) carcinoma is a rare and aggressive variant of muscle invasive bladder cancer (MIBC). Molecular subtyping studies found 5-15% of bladder tumors had transcriptome profiles consistent with NE carcinoma but lacked NE histology (Robertson 2017 , Sjodahl 2017 . Identifying NE variants may have prognostic implications and modify treatment recommendations. In this study, we present a robust genomic classifier trained to identify NE carcinoma.
METHODS: Transcriptome-wide expression profiles were generated for 576 MIBC patients collected from seven institutions. Model training included profiles generated from TURBT and RC specimens from 320 patients prior to treatment with NAC or chemo-radiation. The validation cohort consisted of 256 RC specimens (no prior systemic treatment). Using 10 MIBC-related gene sets, a GLMNET model was built to predict patients with a NE carcinoma expression profile. Uni-and multi-variable survival analyses were used to characterize outcomes of the predicted NE tumors.
RESULTS: In the training set, hierarchical clustering using a panel of 54 genes showed a cluster of 17 patients (5.3%) with a NE carcinoma expression profile. These patients had significantly worse 1 year progression free survival (65% vs 82% for NE vs overall; p¼0.046). In the validation set, 7 tumors were classified (2.7%) as NE with 4 (57%) patients dying from the disease at 1 year after RC. Within 3 years of RC, 100% (7/7) of patients with NE tumors had died. After adjusting for various clinical and pathological factors, patients with predicted NE tumors had a 6.40 increased risk of all-cause mortality (p¼0.001).
CONCLUSIONS: We have developed a gene expression signature that predicts a particularly high-risk group that may need treatment intensification, alternative chemotherapy or clinical trials. Validation will be required to assess the potential clinical utility of this NE carcinoma classifier. AKT/mTOR pathway is critical for bladder cancer (BC) and is aberrantly activated during BC progression. However, few studies have addressed the epigenetic regulation AKT/mTOR signaling. SET and MYND domain-containing protein 3 (SMYD3) is a histone methyltransferase that targets histone H3-K4 for di/trimethylation. In the present study, we determine the role and the underlying mechanism of SMYD3 in the pathogenesis of BC.
Source of
METHODS: The expression of SMYD3 was examined via Western blot, real-time PCR and immunohistochemistry in a cohort of BC tissues. A series of in vivo and in vitro assays was performed to elucidate the contribution and underlying mechanism of the SMYD3/ IGF-1R (insulin-like growth factor-1 receptor)/AKT axis in BC phenotypes and progression.
RESULTS: Strong SMYD3 expression was detected in BC tumors, while normal bladder tissues only showed weak or undetectable signals. The level of SMYD3 expression was positively correlated with tumor stage, lymph node metastasis, histological grade, and poor survival. Depletion of SMYD3 inhibited BC cell proliferation, colony formation, migration, invasion, and xenograft tumor growth. Mechanistically, SMYD3 inhibition abolished the activity of the AKT/mTOR pathway, thereby triggering multiple negative effects on BC cells. Furthermore, SMYD3 activates the expression of IGF-1R, a critical activator of AKT, via inducing hyper-methylation of histone H3-K4 and subsequent chromatin remodeling in the IGF-1R promoter region. Two functional SMYD3-binding motifs were identified.
CONCLUSIONS: Our findings suggest that IGF-1R is a new target gene of SMYD3, and by stimulating IGF-1R transcription, SMYD3 activates the AKT/mTOR pathway, thereby contributing to BC development and progression.
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